These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27626672)

  • 21. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RET inhibition: implications in cancer therapy.
    Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
    Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress and potential impact of RET kinase targeting in cancer.
    Mulligan LM
    Expert Rev Proteomics; 2016 Jul; 13(7):631-3. PubMed ID: 27337654
    [No Abstract]   [Full Text] [Related]  

  • 25. RET fusion as a novel driver of medullary thyroid carcinoma.
    Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ
    J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCDC6: the identity of a protein known to be partner in fusion.
    Cerrato A; Merolla F; Morra F; Celetti A
    Int J Cancer; 2018 Apr; 142(7):1300-1308. PubMed ID: 29044514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RET kinase inhibitors: a review of recent patents (2012-2015).
    Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L
    Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
    Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of
    Mejia Saldarriaga M; Steinberg A; Severson EA; Binder A
    Front Oncol; 2019; 9():1303. PubMed ID: 31850206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.
    Iams WT; Lovly CM
    Cancer Discov; 2018 Jul; 8(7):797-799. PubMed ID: 29967074
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro transforming potential, intracellular signaling properties and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2016 Dec; 23(12):X1. PubMed ID: 27807062
    [No Abstract]   [Full Text] [Related]  

  • 34. Gavreto,
    Am Health Drug Benefits; 2020; 13(5):213-215. PubMed ID: 33343822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Drug Is a Triple Threat Against RET-Altered Cancer.
    Voelker R
    JAMA; 2020 Jun; 323(23):2364. PubMed ID: 32543673
    [No Abstract]   [Full Text] [Related]  

  • 36. Roche buys into RET inhibitor showdown.
    Nat Biotechnol; 2020 Sep; 38(9):1010. PubMed ID: 32887971
    [No Abstract]   [Full Text] [Related]  

  • 37. An Integrative Analysis of the InR/PI3K/Akt Network Identifies the Dynamic Response to Insulin Signaling.
    Vinayagam A; Kulkarni MM; Sopko R; Sun X; Hu Y; Nand A; Villalta C; Moghimi A; Yang X; Mohr SE; Hong P; Asara JM; Perrimon N
    Cell Rep; 2016 Sep; 16(11):3062-3074. PubMed ID: 27626673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coordinate redeployment of PRC1 proteins suppresses tumor formation during Drosophila development.
    Loubière V; Delest A; Thomas A; Bonev B; Schuettengruber B; Sati S; Martinez AM; Cavalli G
    Nat Genet; 2016 Nov; 48(11):1436-1442. PubMed ID: 27643538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional exploration of colorectal cancer genomes using Drosophila.
    Bangi E; Murgia C; Teague AG; Sansom OJ; Cagan RL
    Nat Commun; 2016 Nov; 7():13615. PubMed ID: 27897178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed glial clearance of degenerating axons in aged Drosophila is due to reduced PI3K/Draper activity.
    Purice MD; Speese SD; Logan MA
    Nat Commun; 2016 Sep; 7():12871. PubMed ID: 27647497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.